ClinicalTrials.gg
CompletedNCT00002409Updated Jun 24, 2005

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

A Phase 3 interventional study of Lamivudine/Zidovudine and Abacavir sulfate in HIV Infections, sponsored by Glaxo Wellcome. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
51st of 126
200 · median 154
Phase 3
50 of 132
2 open now
Registered
1st of 132
by date
Lead sponsor
12 of 132
Glaxo Wellcome

Among the 132 studies testing lamivudine in HIV Infections, this one is the 51st largest by enrollment of the 126 interventional ones that give a count, is one of 50 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to see if an HIV-education course can help under-represented, HIV-infected patients. This study examines the areas of faithfulness to drug regimen, level of HIV in the blood, and health status.

Read the detailed description

Following initial screening, eligible patients are treated with open-label Combivir plus abacavir for 24 weeks. Patients are randomized to undergo the education intervention, Tools for Health and Empowerment (T.H.E.) course plus counseling, or routine counseling only (control group). Measurements and evaluations for assessment of immunologic effects, adherence, and health outcomes are performed at entry (Day 1) and at Weeks 2, 5, 8, 12, 16, and 24.

03

Conditions studied

  • HIV Infections

Keywords

  • Drug Therapy, Combination
  • Zidovudine
  • HIV Protease Inhibitors
  • Lamivudine
  • Patient Education
  • Patient Compliance
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Viral Load
  • abacavir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • Documented and confirmed infection.
  • Limited or no experience with antiretrovirals.
  • CD4+ lymphocyte cell count of 50 cells/mm3 or more 14 days prior to study drug administration.
  • HIV-1 plasma RNA above 40 copies/ml and less than 100,000 copies/ml within 14 days prior to study drug administration.
  • Ability to read, comprehend, and record information in fifth-grade English.
  • Ability to attend the 4 sessions of T.H.E. course on Weeks 1-4.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Patients suffering from a serious medical condition such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction which would compromise the safety of the patient.
  • Malabsorption syndrome or other gastrointestinal dysfunction which may interfere with drug absorption or render the patient unable to take oral medication.
  • Acute or chronic active hepatitis.

Concurrent Treatment:

Excluded:

Treatment with foscarnet or other agents with required documented activity against -1 in vitro.

Patients with the following prior conditions are excluded:

  • A clinical diagnosis of AIDS, according to the 1993 Centers for Disease Control (CDC) AIDS surveillance definition. ( below 200 cells/mm3 will not be considered AIDS-defining.)
  • History of allergy to any study drug.

Prior Medication:

Excluded:

  • History of antiretroviral use. Patients with a history of sequential nucleoside monotherapy will be excluded, as will patients with a total antiretroviral history exceeding 6 months.
  • Required treatment with immunomodulating agents, such as systemic , interleukins, vaccines, or interferons, within 4 weeks prior to study entry, or an HIV immunotherapeutic vaccine within 3 months prior to entry. Asthmatic patients using inhaled corticosteroids are eligible for enrollment.

Prior Treatment:

Excluded:

Radiation therapy or cytotoxic chemotherapeutic agents received within 4 weeks prior to entry.

Risk Behavior:

Excluded:

Current alcohol or illicit drug use which may interfere with the ability to comply with dosing schedule and protocol evaluation and assessment.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
200 participants

Interventions

06

Study locations

25 sites
  • AIDS Healthcare Foundation
    Los Angeles, California 90027, United States
  • Oasis Clinic / King Drew Med Ctr
    Los Angeles, California 90059, United States
  • Robert Scott MD
    Oakland, California 94609, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • Whitman Walker Clinic/Elizabeth Taylor Med Ctr
    Washington, District of Columbia 20009, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • Specialty Med Care Ctrs of South Florida Inc
    Miami, Florida 33142, United States
  • Saint Josephs Comprehensive Research Institute
    Tampa, Florida 33607, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Rush Med College / Dept of Infectious Diseases
    Chicago, Illinois 60612, United States
  • Encounter Med Group
    Oak Park, Illinois 60301, United States
  • New England Med Ctr / Div of Geo Med & Infect Disease
    Boston, Massachusetts 02111, United States
  • Jeffrey Bomser Clinic / NJCR
    Newark, New Jersey 07103, United States
  • UMDNJ / Dept of Ob/Gyn
    Newark, New Jersey 07103, United States
  • Newark Community Health Ctr
    Newark, New Jersey 07114, United States
  • Addiction Research and Treatment Corp
    Brooklyn, New York 11201, United States
  • Bentley-Salick Med Practice
    New York, New York 10011, United States
  • Holmes Hosp / Univ of Cincinnati Med Ctr
    Cincinnati, Ohio 452670405, United States
  • Allegheny Univ of the Hlth Sciences / Div of Infect Diseases
    Philadelphia, Pennsylvania 19102, United States
  • Carolina Family Care/Denmark Med Ctr / P O Box 278
    Denmark, South Carolina 29042, United States
  • Univ of Tennessee
    Memphis, Tennessee 38103, United States
  • Univ of Tennessee / Div of Infect Dis / Dept of Med
    Memphis, Tennessee 38165, United States
  • Southeast Dallas Health Ctr
    Dallas, Texas 75217, United States
  • Therapeutic Concepts
    Houston, Texas 77004, United States
  • Santa Rosa Med Ctr / Baptist Med Ctr
    San Antonio, Texas 78205, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002409
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Jun 24, 2005

Study contacts

K Rawlings
study chair
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 1999. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Zidovudine · Abacavir

Start the discussion